Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | CPB1 | P15086 | 1/20 | 0.48 |
| ▸ | CPA2 | P48052 | 1/20 | 0.48 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.47 |
| ▸ | REN | P00797 | 2/20 | 0.47 |
| ▸ | GNPAT | O15228 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2633286 | 1.00 | ALDH1A1 (0.50) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL2632731 | 0.88 | CPA1 (0.50) | ALDH1A1CPA1CPA2CPA4PSMB5 | |
| SCHEMBL14208789 | 0.87 | TACR1 (0.60) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL14208698 | 0.87 | TACR1 (0.60) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL2759971 | 0.87 | REN (0.45) | ALDH1A1CPA1CPB1CPA2CPA4 | |
| SCHEMBL9486892 | 0.86 | TACR1 (0.61) | ALDH1A1TACR1GNPAT | |
| SCHEMBL9488064 | 0.86 | TACR1 (0.61) | ALDH1A1TACR1GNPAT | |
| SCHEMBL2633304 | 0.84 | REN (0.43) | CPA1CPB1CPA2CPA4ACE2 | |
| SCHEMBL14232442 | 0.84 | REN (0.43) | CPA1CPB1CPA2CPA4ACE2 | |
| SCHEMBL10105785 | 0.84 | ALDH1A1 (0.57) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088741-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, CPN1 | ALDH1A1 3376/4885THRB 3055/4885CYP2C9 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.